#USA #New York #Healthcare Investments #CDR Funds #Caforio

Giovanni Caforio Joins CD&R as Operating Advisor

In a strategic move to bolster its healthcare portfolio, CD&R (Clayton, Dubilier & Rice) has announced the appointment of Giovanni Caforio as an Operating Advisor. As a seasoned veteran of the biopharmaceutical industry with a remarkable 35-year career, Caforio is expected to play a crucial role in identifying and evaluating new investment opportunities within the healthcare sector for CD&R funds.

Dr. Caforio brings a wealth of experience to the table, currently serving as Chair at Novartis, a Swiss-based multinational pharmaceutical giant. He has been at the helm of Novartis' board since 2025, following an illustrious tenure at Bristol Myers Squibb (BMS), where he ascended from various leadership roles to the CEO position in May 2015. Under his stewardship, BMS launched 12 innovative medicines and tripled its revenue. His leadership was marked by strategic acquisitions that significantly expanded the company's reach and capabilities within the biopharmaceutical landscape, underscoring his belief in the power of healthcare innovation.

Dave Novak, Co-President of CD&R, expressed enthusiasm over Caforio’s unique qualifications. “CD&R has always been defined by our ability to partner with world-class leaders who possess deep industry expertise. Giovanni’s extensive background will be an invaluable asset as we pursue growth opportunities and support our management teams in driving value creation,” he stated.

For his part, Caforio articulated his alignment with CD&R’s investment philosophy, emphasizing the importance of collaboration with management teams in building sustainable businesses. “I understand that real transformation in the biopharma sector can be achieved through operational excellence coupled with a patient-centered approach,” he remarked. His commitment to leveraging his knowledge and experience is evident as he embarks on this new journey with CD&R.

Eric Rouzier, a partner at CD&R, highlighted the dynamic nature of the healthcare sector, driven by scientific advancements and evolving patient needs. He views Caforio’s expansive experience as a game changer for CD&R as it continues to build its healthcare portfolio.

Dr. Caforio is not only a distinguished business leader but also a qualified medical doctor, having graduated from the prestigious Sapienza University in Rome, Italy, in 1988. His linguistic capabilities span across Italian, French, Spanish, Portuguese, and English, which enhances his ability to work in a global investment environment.

CD&R itself is a venerable private investment firm established in 1978, known for its approach that integrates significant operational capabilities with investment acumen. The firm primarily focuses on nurturing sustainable business growth, leveraging its partnership with management teams across various industries, including healthcare, consumer goods, technology, and financial services. CD&R takes a long-term view on value creation and prioritizes a positive impact through its investments. With offices in New York and London, CD&R is privately owned and committed to building lasting businesses through partnership and expertise.

As Caforio steps into his new role, anticipation builds on the transformative changes he might spur within CD&R’s investment strategies, especially in the ever-evolving healthcare sector. The collaboration signals a strategic alignment of biopharmaceutical leadership with private investment goals, potentially leading to innovative approaches in identifying and managing impactful healthcare investments.